Abstract: The instant invention relates to a method for reducing the risk for development of anti-viral treatment resistance due to an HIV mutation in a human subject infected with HIV, comprising administering EFdA in combination with one or more anti-viral agents.

Abstract: The present invention relates to a compound of the formula (I), (II) or (III), to the use of the compound in an electronic device, and to an electronic device comprising a compound of the formula (I), (II) or (III). The present invention furthermore relates to a process for the preparation of a compound of the formula (I), (II) or (III) and to a formulation comprising one or more compounds of the formula (I), (II) or (III).

Abstract: Compounds of formula I, (R11O)sSi(CH3)3?s-Sp11-NR12-Sp12-C(OR13)tH3?t??I wherein the variable groups are as defined herein are useful as adhesion promotors in polymerizable liquid crystal (LC) material.

Abstract: The present invention relates to novel compounds containing fluorinated end groups and to the use thereof in, for example, dirt-repellent coatings.

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.

Abstract: The invention relates to polycondensed lactam compounds as materials for use in electronic devices, and electronic devices, in particular organic electroluminescent devices, containing said materials.

Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Abstract: The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, in which R1, R1*, rings A and B, Z1, L1, L2, a and b have the meanings indicated in Claim 1, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, IPS or PS-IPS effect.

Abstract: The present invention relates to a liquid-crystal medium which comprises one or more compounds each of formulae I and II in which the occurring groups and parameters have the meanings given in claim 1.

Abstract: The present invention relates to Compounds of Formula (I): Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, Ra, Rb, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treating or preventing HIV infection in a subject.

Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Abstract: The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.

Abstract: The present invention relates to the field of tracing and anti-counterfeit protection of physical objects, and particularly to preparing and performing a secure authentication of such objects. Specifically, the invention is directed to a method and a system for preparing a subsequent secured authentication of a physical object or group of physical objects by a recipient thereof, to a method and system for authenticating a physical object or group of physical objects, to a method and system of securely providing a time-variant combination scheme for authenticating a physical object or group of physical objects according to the above methods, and to related computer programs corresponding to said methods. The invention is based on the concept of increasing the security level by increasing the information entropy of the data on which the anti-counterfeit protection is based by means of random data communicated to authenticating entities in an algorithmically hidden way.

Abstract: The present invention relates to novel compounds, particularly to hydrophilic compounds, comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices. The present application also relates to ophthalmic devices comprising such compounds.

Abstract: A switchable optical element and method for detecting breakage of a substrate (A, B) of at least one switchable optical element (10) having a first substrate (A) and a second substrate (B), the first substrate (A) being coated with a first electrode and the second substrate (B) being coated with a second electrode, and a switchable layer (14), the switchable layer (14) being sandwiched between the first substrate (A) and second substrate (B), the first electrode and second electrode each having at least one contact, by i) measuring a change in a differential signal measured at two contacts of a substrate (A, B), ii) measuring a change in capacitance between the two substrates (A, B), iii) measuring a change in resistance of at least one of the substrates (A, B), iv) measuring a change in current applied to the switchable optical element (10).

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: The present invention relates to a composition and to a method of manufacturing a composition.

Abstract: The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

Abstract: The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, comprising these compounds.